Mobilize Against Malaria (MAM) is Pfizer's signature philanthropic program to combat malaria. MAM is a five-year (2007–2011), $15M initiative announced at the Clinton Global Initiative in 2006, designed to address critical gaps in malaria treatment and education in Ghana, Senegal and Kenya.
The purpose of the MAM Initiative is to reduce malaria morbidity and mortality through the effective delivery of Artemisinin-based Combination Therapy (ACT), the national standard for treating uncomplicated malaria in Ghana, Kenya and Senegal. Each of Pfizer's three MAM programs uses a dual-pronged approach that addresses both the supply of quality public healthcare, as well as communities' demand for treatment. Specifically, MAM aims to: Improve malaria symptom recognition, treatment, and referral through targeted training activities; and Support complementary community mobilization campaigns to strengthen the demand for prompt and effective malaria treatment.
In each of the three program countries, Pfizer provides support to leading non-governmental organizations (NGO) to implement and evaluate effective malaria interventions. These partners include Family Health International (FHI), Ghana Social Marketing Foundation (GSMF), Health Partners Ghana, Population Services International (PSI), KEMRI-Welcome Trust and IntraHealth International.
|Value||USD 15 Million|